We strongly believe that the key elements to a successful and lasting partnership are trust, shared values and openness. To revolutionize today’s standard of care, we are looking for best or first in class innovation in the following areas:

CARDIOVASCULAR, RENAL & METABOLIC DISEASE

We are highly committed to making a contribution to areas of huge unmet need and societal burden through transformative science and expanding its footprint in cardiovascular and metabolic diseases.

Partnering opportunities we are looking for:

• Uncontrolled hypertension
• Obesity (also in context of Diabetes)
• MASH (metabolic dysfunction-associated steatohepatitis)
• Myocardial infarction/ stroke secondary prevention
• Cardiomyopathies
• SPAF (stroke & systemic embolic prevention in atrial fibrillation)

DIGITAL AND DATA

We are interested in collaborations on real world data, advanced analytics, digital tools and platform opportunities that:

• Enable infrastructure to train new AI models
• Expand our portfolio (novel targets, line extensions, combinations, etc.)
• Improve PTS and cycle times
• Increase product potential

IMMUNOLOGY

We are leading the way to advance science in inflammatory and autoimmune diseases. Partnering opportunities we are looking for:

• Gastroenterology (IBD), Respiratory (COPD, Asthma, IPF, ILD, SSc), Nephrology (GN, CKD, Transplant, auto-immune skin diseases (Psoriasis, AD), T1D, Celiac disease
• Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets

INFECTIOUS DISEASES

We are advancing innovation to combat infectious diseases like HBV, influenza and MDR. Partnering opportunities we are looking for:

• Hepatitis B
• Multidrug-resistant, Gram-negative Bacterial Infections

Neurology

Partnering opportunities we are looking for:

• Neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease)
• Neuroinflammation (e.g. Multiple sclerosis)
• Neuromuscular diseases (e.g. ALS, Duchenne Muscular Dystrophy)
• Transformational therapies in other CNS indications

ONCOLOGY AND HEMATOLOGY

We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy. Partnering opportunities we are looking for:

Tumour types

• Breast
• Lung
• Malignant haematology (including multiple myeloma (MM), lymphoma, acute myeloid leukemia (AML))
• Transformative therapies in other indications - notably including colorectal cancer (CRC), prostate, bladder

Pathways/modalities

• Oncogenic drivers
• Cancer cell dependencies
• Antibody Drug Conjugates (ADCs)
• Cancer immunotherapy - including T-cell engagers (TCEs), bispecifics, innate and stromal cell
• Allogeneic cell therapies

OPHTHALMOLOGY

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting-edge research. Partnering opportunities we are looking for:

• Retinal diseases and long-acting ocular drug delivery solutions
• Glaucoma and dry eye disease

RESEARCH TECHNOLOGIES

We focus on therapeutic modalities and enabling technologies. Partnering opportunities we are looking for:

• New mechanism of actions and enabling technologies to expand the druggable target space (across therapeutic modalities)
• Targeted delivery
• Genomic Medicine platforms
• Novel target discovery
• ML-enabled drug discovery

PHARMA PARTNERING IN ASIA

Research & Development is the essence and lifeblood of Roche - and we have a unique way to foster innovation together with our partners in Asia and across the world. Partnering opportunities we are looking for:

• Innovative biotechs or academic institutions from Asia working on first in class or best in disease opportunities from Discovery to Phase II Development and;
• Immunology (interferon-driven inflammatory diseases including lupus nephritis and systemic sclerosis, nephrology and renal transplant, with focused MoAs in nucleic acid sensing, interferon production, complement and immune tolerance) and oncology (gastrointestinal cancers, with focused MoAs in novel and/or disease-specific cancer driver genes, synthetic lethality, immunotherapy for enhancing innate immunity and dampening suppression, and cancer extracellular matrix esp. collagen modulation)

PHARMA PARTNERING IN THE UNITED KINGDOM

Leveraging external innovation has always been central to our R&D strategy and, as such, supporting, encouraging and accessing early stage innovation is a critical aspect of our ability to discover and develop meaningful medicines for patients. Since some of the most cutting-edge science is happening in the UK, we are increasingly focusing on identifying and supporting great science in the UK. We are seeking partnering opportunities across all our therapeutic areas of interest, including digital and personalized healthcare and novel research technologies, in particular for the following:

• Novel targets
• Potential first- or best-in class molecules
• Novel enabling modalities
• Data sets and advanced analytics
• Digital and mobile technologies

ALLIANCE & ASSET MANAGEMENT

During the collaboration conversations, a dedicated Alliance Director is assigned as the single point of contact to ensure successful continuation and an enduring relationship with our new partner.

R&D OUT-LICENSING AND COMMERCIAL ASSET DIVESTMENT

Out-licensing and divestment decisions enable us to continue our investment in innovative R&D, supporting the development of novel medicines. In addition, it supports the further development of programs that could result in treatments for patients in disease areas and indications that are no longer of strategic focus for Roche and Genentech.